News und Analysen
EnWave berichtet das dritte Quartal des Geschäftsjahres 2020 am 27. August 2020 und gibt Update zu NutraDried
Vancouver, B.C., 20. August 2020 - Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ), ein
EnWave to Report Third Quarter Fiscal 2020 Financial Results on August 27, 2020 and Provides NutraDried Update
Vancouver, B.C., August 20th, 2020 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ), a global
Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the publication of interim results from its Phase II CONTROL trial of neratinib in the September 2020 Issue (Volume
Momenta Pharmaceuticals: Nächste Mega-Übernahme im US-Biotechsektor!
Zuletzt verging kaum ein Tag, an dem nicht irgendeine Mega-Übernahme im US-Biotechsektor vermeldet wurde. So auch heute. Denn heute verkündete Johnson & Johnson die Übernahme von Momenta
True Leaf Enters into Asset Purchase Agreement to Sell True Leaf Pet Inc.
Vernon, BC - August 19, 2020 - True Leaf Brands Inc. (CSE: MJ) (OTC Pink: TRLFF) (FSE: TLA) (“True Leaf”) announced today that, as part of the sales process approved by Order of the British
True Leaf schließt Vereinbarung über den Verkauf von True Leaf Pet Inc. ab
Vernon (British Columbia), 19. August 2020. True Leaf Brands Inc. (CSE: MJ) (OTCQX: TRLFF) (FWB: TLA) („True Leaf“) gibt heute bekannt, dass True Leaf Pet Inc. („TLP“) im Rahmen des
Relay Medical und Fio Corporation gründen Joint Venture für Pandemie-Testmethode
19. August 2018 – Relay Medical Corp. („Relay“ oder das „Unternehmen“) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) und Fio Corporation („Fio“) freuen sich, die Gründung eines Joint Ventures („J
Relay Medical and Fio Corporation Announce Joint Venture for Pandemic Testing Technology
August 19, 2020 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), and Fio Corporation (“Fio”) are pleased to announce the establishment of a joint
QIAGEN bestärkt COVID-19-Forschung mit integrierten Coronavirus-NGS- und Software-Lösungen
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat das innovative QIAseq-SARS-CoV-2-Primer-Panel für Next-Generation-Sequencing (NGS) des Genoms des neuartigen Coronavirus sowie integrierte
QIAGEN Expands Integrated Coronavirus NGS and Software Solutions to Accelerate COVID-19 Research
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) launched the innovative QIAseq SARS-CoV-2 Primer Panel for next-generation sequencing (NGS) of the novel coronavirus genome, along with integrated
Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that the Journal of Clinical Oncology has published results from its Phase 1 study of QINLOCK, the Company’s switch-control tyrosine
Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that data from the Phase 2 TRITON2 study of Rubraca® (rucaparib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
GNI Group Ltd. Announces Positive Results From the Phase II Study of F351 as Therapy for HBV-related Liver Fibrosis in China
GNI Group Ltd. (GNI Group; TSE Mothers 2160), a commercial-stage biopharmaceutical company, today announced positive results from the initial analysis of Phase II clinical trial of the F351 drug
Relay Medical and Fio Corporation Extend MOU Agreement for Collaboration on a Rapid Diagnostic Testing Platform
August 16, 2020 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), and Fio Corporation (“Fio”) jointly report that the Companies have extended the me
Relay Medical und Fio Corporation verlängern ihre Absichtserklärung bezüglich der Zusammenarbeit im Hinblick auf eine Schnelltest-Diagnoseplattform
16. August 2020 – Relay Medical Corp. („Relay“ oder das „Unternehmen“) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) und Fio Corporation („Fio“) berichten gemeinsam, dass die Unternehmen ihre am
Sensorion to present at the Oppenheimer Life Sciences Company Call Series and Virtual World Orphan Drug Congress USA
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Navidea Biopharmaceuticals Reports Second Quarter and Year-to-Date 2020 Financial Results
Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced
QIAGEN wird erfolgreiche Wachstumsstrategie mit Fokus auf Umsetzung und mehr Wertschöpfung weiterverfolgen, nachdem das freiwillige öffentliche Übernahmeangebot von Thermo Fisher gescheitert ist
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, seine erfolgreiche Wachstumsstrategie mit dem Ziel einer deutlichen Wertsteigerung für Aktionäre und andere
QIAGEN to Continue Successful Growth Strategy Focused on Execution and Greater Value Creation After Voluntary Public Takeover Offer Falls Short
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will continue to execute its successful growth strategy aiming to create significant value for shareholders and other
Novocure Announces Expansion of Its Executive Leadership Team
Novocure (NASDAQ:NVCR) today announced an expansion of its Executive Leadership Team, effective Sept. 1, 2020, intended to further solidify executive leadership in preparation for an anticipated
Evotec: Weiter auf Wachstumskurs
Am Dienstag vermeldete Evotec (WKN: 566480) einen neuen Partner-Deal mit Resolute Therapeutics und CARB-X im Bereich Infektionskrankheiten und antimikrobielle Resistenzen. Heute schiebt der
IMV Inc. Announces Second Quarter 2020 Financial Results
IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases
NeutriSci: Neuigkeiten zur Produkteinführung in Kalifornien
Vancouver, British Columbia – 12. August 2020 – NeutriSci International Inc. („NeutriSci“ oder das „Unternehmen“) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) – ein innovatives
NeutriSci Provides Update Regarding Product Launch in California
Vancouver, British Columbia – August 12, 2020 – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company
Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (Aurinia or the Company) today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent